ACV in Taiwan. What’s Next? A Review of ACV’s strategies and future in Taiwan.
dc.contributor | 沈永正 | zh_TW |
dc.contributor | Shen, Yung-Cheng | en_US |
dc.contributor.author | POWEN LEE | zh_TW |
dc.contributor.author | Lee, Po-Wen | en_US |
dc.date.accessioned | 2019-09-03T09:53:22Z | |
dc.date.available | 不公開 | |
dc.date.available | 2019-09-03T09:53:22Z | |
dc.date.issued | 2017 | |
dc.description.abstract | 無中文摘要 | zh_TW |
dc.description.abstract | A proud family-owned dermatological pharmaceutical company started in Auckland, New Zealand in 1950, ACV Healthcare began its global invasion in the 1990s. After successful landing in the Middle East after the gulf war, ACV turned its attention to the (South) East Asia countries, Hong Kong, Singapore, Malaysia and Taiwan. More than a decade after investing in the region, Taiwan remains as one of ACV’s biggest headache in Asia. Not only did it experience a series of setbacks including mediocre performances, parting ways with its long-term distributor, and its country manager recently, ACV also faces transformation from a more medical channel focus strategy to consumer channels focus. This paper highlights some of the difficulties ACV faces in the marketplace in the past five years and ACV’s strategies in terms of pricing, channel and HR. | en_US |
dc.description.sponsorship | 國際企業管理雙碩士學位學程(NTNU-USC DIMBA) | zh_TW |
dc.identifier | G0105596104 | |
dc.identifier.uri | http://etds.lib.ntnu.edu.tw/cgi-bin/gs32/gsweb.cgi?o=dstdcdr&s=id=%22G0105596104%22.&%22.id.& | |
dc.identifier.uri | http://rportal.lib.ntnu.edu.tw:80/handle/20.500.12235/94454 | |
dc.language | 英文 | |
dc.subject | Cosmetics | zh_TW |
dc.subject | Pharmaceutical | zh_TW |
dc.subject | ACV | zh_TW |
dc.subject | Pharmaceutical | en_US |
dc.subject | ACV | en_US |
dc.subject | Cosmetics | en_US |
dc.title | ACV in Taiwan. What’s Next? A Review of ACV’s strategies and future in Taiwan. | zh_TW |
dc.title | ACV in Taiwan. What’s Next? A Review of ACV’s strategies and future in Taiwan. | en_US |